1,271 reports of this reaction
2.6% of all ENALAPRIL MALEATE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for ENALAPRIL MALEATE, manufactured by Bausch Health US LLC. There are 1,271 FDA adverse event reports linking ENALAPRIL MALEATE to DYSPNOEA. This represents approximately 2.6% of all 48,429 adverse event reports for this drug.
Patients taking ENALAPRIL MALEATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ENALAPRIL MALEATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ENALAPRIL MALEATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,271 FDA reports for ENALAPRIL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.6% of all adverse event reports for ENALAPRIL MALEATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking ENALAPRIL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.